Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Vanderbilt researchers create massive transcriptomic atlas of breast cancer (opens in a new tab)

news-medical.net · 2026-11-03

Short answerEvidenceSource

Short answer

Not assessed

Check incomplete.

We found a likely source study, but its evidence could not be prepared for claim review. The article's claims remain unverified.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Source study identified.

A source study was identified, but the study's evidence could not be prepared for claim assessment. No claim verdicts are available.

View article claims
3
Then inspect each claim

Evidence layer

Claim by claim

A source study was identified, but the study's evidence could not be prepared for claim assessment. The claims below have not been assessed.

Claim 1 of 4Not checkedResearchers at Vanderbilt-Ingram Cancer Center published a study in Cell Reports Medicine on Nov. 3 that generated one of the largest transcriptomic maps of breast cancer ever assembled, integrating data from more than 7,600 tumors across 22 independent studies.View evidenceHide evidence

As statedmore than 7,600 tumors across 22 independent studies

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 2 of 4Not checkedThe atlas provides an unprecedented view of breast cancer’s molecular diversity and reveals distinct tumor populations associated with different clinical outcomes, biological characteristics, and therapeutic vulnerabilities.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 3 of 4Not checkedThe study says estrogen receptor-low breast cancers behave more like ER-negative disease, identifies subsets of HER2-positive tumors that may benefit from HER2 kinase inhibitors, uncovers a hidden neuroendocrine form associated with worse outcomes after standard chemo-endocrine therapy and possible FGFR1 targeting, and defines a biologically distinct aggressive basal-luminal progenitor triple-negative subtype with potential vulnerabilities to RTK/MAPK-targeted and anti-angiogenic therapies.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 4 of 4Not checkedResearchers also created a tool that can assign tumors to subtypes using standard bulk RNA sequencing data, with the goal of guiding future research studies and clinical trials; they say prospective testing is needed to determine whether subtype-guided treatment improves outcomes.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

An integrated breast cancer transcriptomic atlas defines clinical subtypes and informs cellular origin

Cell Reports Medicine · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

Selected

An integrated breast cancer transcriptomic atlas defines clinical subtypes and informs cellular origin

Cell Reports Medicine · 2026 · Crossref

Source (opens in a new tab)

And 10 more candidates considered.